Alto Neuroscience, Inc.는 미국에서 임상 단계의 바이오 제약 회사로 활동하고 있습니다. 이 회사의 제품 파이프라인에는 양극성 우울증(BPD) 환자 치료를 위해 2b상 임상 시험 중인 ALTO-100이 포함됩니다. 또한, 주요 우울 장애(MDD) 환자 치료를 위해 2b상 임상 시험 중인, 항우울 특성을 가진 소분자 멜라토닌성 작용제 및 세로토닌성 길항제인 ALTO-300을 개발하고 있습니다. 이 외에도 다음 제품들을 개발 중입니다: 조현병 관련 인지 장애 치료를 위해 2상 개념 증명(POC) 임상 시험 중인
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.